<DOC>
	<DOCNO>NCT02632812</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomize , parallel trial evaluate rebamipide reduce number gastric event cause naproxen . Sample size 24 participant ( 12 per treatment group ) , male female , age 18 years-old . Primary objective compare rebamipide effervescent granule 100 mg twice daily , plus naproxen ( coated tablet ) 550 mg twice daily placebo plus naproxen 550 mg twice daily , seven day , reduction gastric event cause naproxen . Secondary objective evaluate safety tolerability rebamipide multiple administration . Participants receive either rebamipide + naproxen placebo + naproxen , , 7 consecutive day , accompany follow-up visit . Gastric integrity assess , treatment , endoscopy , stomach biopsy detection H. pylorus . Additionally , detection occult blood stool perform , treatment . From above-mentioned biopsy , dosage prostaglandin E2 histopathological analysis perform .</brief_summary>
	<brief_title>Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Male female study participant , age 18 yearsold ; woman pregnant breastfeed ; Body mass index ( BMI ) great equal 19 less equal 28.75 Kg/m2 ; Good health condition without significant disease , accord best medical judgement , accord protocol requirement study evaluation : medical history , blood pressure heart rate measurement , physical examination , electrocardiogram ( ECG ) screen laboratory test ; Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity investigational product ( naproxen rebamipide ) chemically related compound ; history serious adverse reaction hypersensitivity drug ; Subject present intact superior gastrointestinal mucosa , i.e. , present bleeding , ulcer apparent injury baseline endoscopy ; Subject achlorhydria ( intragastric pH &gt; 6.5 ) ; History presence hepatic gastrointestinal disease , condition interferes drug absorption , distribution , excretion metabolism ; Chronic therapy drug , except oral contraceptive ; History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic psychiatric disease ; hypotension hypertension , etiology , require pharmacological treatment ; history myocardial infarction , angina and/or heart failure ; Occult blood stool treatment ; Electrocardiographic finding , investigator criterion , recommend study participation ; Deviations screen laboratory result consider clinically relevant principal investigator ; History drug alcohol addiction excessive alcohol consumption ( &gt; 35 g/day ) ; Use regular medication within 2 week prior study enrollment use medication within one week prior study enrollment , except oral contraceptive case , base drug 's metabolite 's halflife , complete elimination assume ; Treatment , within 6 month trial , drug know wellestablished toxic potential major organ ; Participation experimental research administration experimental drug within 6 month trial ; Any condition , accord investigator 's best judgement , prevents subject participate trial ; Pregnancy , labor miscarriage 12 week admission predict date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>